BNT162b2 Vaccine Effectiveness Against Omicron in Children Aged 5–11 Years

Since its detection in November 2021, the Omicron SARS-CoV-2 variant (and its subvariants) has predominated and has been responsible for sustaining the worldwide COVID-19 pandemic. The current vaccines provide less protection against infection with Omicron compared with previous variants. The Pfizer-BioNTech vaccine (BNT162b2) was granted emergency use authorization in the U.S. for children aged 5-11 years in the fall of 2021, prior to Omicron's emergence. In a national cohort study in Singapore from January 21, 2022, through April 8, 2022, researchers estimated the effectiveness of partial (one dose) and complete (two doses) administration of the Pfizer-BioNTech vaccine against the earliest of the Omicron subvariants in children aged 5–11 …